9 results match your criteria: "Centre régional de Pharmacovigilance de Lille[Affiliation]"
Could direct oral anticoagulants induce non-hemorrhagic joint disorders?
Therapie
June 2024
Service de médecine interne, centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), CHU de Lille, UFR de médecine, université de Lille, 59000 Lille, France.
Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.
Eur J Clin Pharmacol
December 2019
Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, INSERM U1027, Faculté de Médecine, Centre Hospitalier Universitaire, Toulouse, France.
Introduction: Osteomalacia and osteoporosis are two metabolic bone disorders that increase the risk of fracture due to several causes. In terms of drugs, apart from corticosteroids, which are known to induce bone disorders, several other drugs used in chronic disease management have also been linked with an increased risk of osteoporosis and osteomalacia.
Purpose: The aim of this study was to describe spontaneous reports of drug-induced osteoporosis and osteomalacia in the French (FPVDB) and Spanish (SPVDB) pharmacovigilance databases.
Pristinamycin-induced arthralgia and myalgia: Analysis of the French Pharmacovigilance Database.
Med Mal Infect
February 2018
Centre régional de pharmacovigilance de Lille, faculté de médecine, CHRU de Lille, 1, place de Verdun, 59037 Lille cedex, France. Electronic address:
Introduction: Pristinamycin is an antibiotic of the streptogramin family; few adverse effects of this drug are reported, only cutaneous and digestive ones. Arthralgia and myalgia may however be observed although not mentioned in the summary of product characteristics.
Objective: Description and analysis of cases of pristinamycin-induced arthralgia and/or myalgia registered in the French database of pharmacovigilance.
[Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database].
Rev Med Interne
May 2017
Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France.
Introduction: Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated.
Case Report: We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus.
[Tamoxifen: a surprising prescription in a bodybuilder].
Presse Med
February 2015
CHRU de Lille, centre régional de pharmacovigilance de Lille, service de pharmacologie, 59037 Lille cedex, France.
[Weight gain during treatment with thalidomide: a case report].
Therapie
February 2015
Service de dermatologie, Centre hospitalier universitaire de Lille, France.
We report a case of weight gain induced by thalidomide in a 39-year-old female patient with Behçet's disease treated for an indication of severe, bipolar, aphthous stomatitis.
View Article and Find Full Text PDF[Cytolysis in an elderly patient treated with dabigatran etexilate].
Therapie
January 2014
Centre régional de Pharmacovigilance de Lille, CHRU Lille, Faculté de Médecine, Lille, France.
[Microscopic colitis in a patient treated with duloxetine].
Therapie
January 2014
Centre régional de Pharmacovigilance de Lille, CHRU Lille, Faculté de Médecine, Lille, France.
[Tachycardia and precordial pain with agomelatine: a case report].
Therapie
January 2014
Centre régional de Pharmacovigilance de Lille, Faculté de Médecine, Lille, France.